News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MedImmune (AZN) Deal Exposes Early-Stage University of California, San Francisco (UCSF) Drugs


2/12/2014 7:42:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MedImmune is looking to UCSF researchers to feed its drug pipeline. In a three-year deal with the University of California, San Francisco's Clinical and Translational Science Institute, the biologics R&D unit of AstraZeneca hopes to spot potential early-research drugs for a wide-range of diseases, including cancer, heart disease, metabolic diseases, neuroscience and infectious diseases. Financial terms of the deal were not disclosed.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES